Fundraising Fox
Intellia Therapeutics
NASDAQ: NTLACambridge, US · Founded 2014 · Delaware corporation · 505 employees on LinkedIn · 8 known investors
Find your way into Intellia Therapeutics
Sign up to see every warm intro you have to Intellia Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Intellia Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.
Founders & leadership
Intellia Therapeutics was founded in 2014 by Nessan Bermingham and Jennifer Doudna.
Investors · 8
How we know: age1's portfolio page · Not right? Tell us
How we know: Atlas Venture's portfolio page · board seat on SEC Form D · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: OrbiMed's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: Ridgeback Capital's portfolio page · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$70M disclosed across 1 of 2 rounds · 2015–2026
▶$70MraisedSep 2015 · 28 investors · BiotechnologyRule 506(b)
- Nessan BerminghamExecutive Officer, Director
- Jose RiveraExecutive Officer
- Carl GordonDirector
- Jean-Francois FormelaDirector
- John LeonardExecutive Officer, Director
- Rachel HaurwitzDirector
- Offering amount
- $70M
- Amount sold
- $70M
- Sales commissions
- $2.3M
- Placement agents
- Leerink Partners LLC
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
5 people who came through Intellia Therapeutics went on to found or lead other companies.
Related companies · 2
Companies working in the same space as Intellia Therapeutics.
Frequently asked questions
- What does Intellia Therapeutics do?
- Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.
- Who founded Intellia Therapeutics?
- Intellia Therapeutics was founded by Nessan Bermingham, Jennifer Doudna in 2014.
- Who are Intellia Therapeutics's investors?
- Intellia Therapeutics's investors include age1, Atlas Venture, Avoro Capital Advisors, EcoR1 Capital, Foresite Capital, OrbiMed, Ridgeback Capital, Fidelity Investments.
- How much funding has Intellia Therapeutics raised?
- Intellia Therapeutics has disclosed $70M raised across 1 of its 2 known rounds.
- Where is Intellia Therapeutics headquartered?
- Intellia Therapeutics is headquartered in Cambridge, US.